Medivir AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MVRBF research report →
About the company
Medivir AB (publ), established in 1987 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to the discovery, development, and commercialization of medicines, with a primary emphasis on oncology. The company's operations span both Sweden and international markets. Currently, Medivir markets Zoviduo (formerly Xerclear) for the treatment of labial herpes.
- CEO
- Jens Lindberg
- IPO
- 2010
- Employees
- 10
- HQ
- Huddinge, SE
Price Chart
- Market Cap
- $45.78M
- P/E
- -4.51
- P/S
- 91.27
- P/B
- 2.09
- EV/EBITDA
- -4.82
- Div Yield
- 0.00%
- Gross Margin
- -1467.11%
- Op Margin
- -1981.72%
- Net Margin
- -2024.07%
- ROE
- -37.65%
- ROIC
- -41.94%
- Revenue
- $4.41M · -82.74%
- Net Income
- $-88,765,000 · -40.62%
- EPS
- $-1.59 · -32.50%
- Op Income
- $-87,354,000
- FCF YoY
- -109.71%
- 52W High
- $0.90
- 52W Low
- $0.68
- 50D MA
- $0.82
- 200D MA
- $0.76
- Beta
- 0.36
- Avg Volume
- 0
Get TickerSpark's AI analysis on MVRBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MVRBF coverage
Recent articles, reports, and earnings notes.
No research on MVRBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MVRBF report →Similar companies
Peers in the same neighborhood.